[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX349321B - Terapia combinada. - Google Patents

Terapia combinada.

Info

Publication number
MX349321B
MX349321B MX2014000199A MX2014000199A MX349321B MX 349321 B MX349321 B MX 349321B MX 2014000199 A MX2014000199 A MX 2014000199A MX 2014000199 A MX2014000199 A MX 2014000199A MX 349321 B MX349321 B MX 349321B
Authority
MX
Mexico
Prior art keywords
combination therapy
individuals
cancer
minimising
progression
Prior art date
Application number
MX2014000199A
Other languages
English (en)
Other versions
MX2014000199A (es
Inventor
Alexander Barden Julian
Gidley-Baird Angus
Original Assignee
Biosceptre (Aust) Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2011902623A external-priority patent/AU2011902623A0/en
Application filed by Biosceptre (Aust) Pty Ltd filed Critical Biosceptre (Aust) Pty Ltd
Publication of MX2014000199A publication Critical patent/MX2014000199A/es
Publication of MX349321B publication Critical patent/MX349321B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a un receptor P2X7 o un fragmento del mismo para usarse en un método para minimizar la progresión del cáncer en un individuo, en donde el individuo ha recibido un sitio no propio de unión de antígenos para el tratamiento del cáncer, en donde el fragmento de un receptor P2X7 es capaz de formar una respuesta inmunitaria a un receptor P2X7, y que incluye una secuencia de aminoácidos seleccionada del grupo que consiste en SEQ ID NO: 2, 3 y 4.
MX2014000199A 2011-07-01 2012-07-02 Terapia combinada. MX349321B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2011902623A AU2011902623A0 (en) 2011-07-01 Combination therapy
PCT/AU2012/000795 WO2013003895A1 (en) 2011-07-01 2012-07-02 Combination therapy

Publications (2)

Publication Number Publication Date
MX2014000199A MX2014000199A (es) 2014-06-11
MX349321B true MX349321B (es) 2017-07-21

Family

ID=47436374

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014000199A MX349321B (es) 2011-07-01 2012-07-02 Terapia combinada.

Country Status (11)

Country Link
US (3) US9566318B2 (es)
EP (1) EP2726095B1 (es)
JP (2) JP6305920B2 (es)
CN (1) CN103702683B (es)
AU (1) AU2012278921B2 (es)
BR (1) BR112013033974A2 (es)
CA (1) CA2840251C (es)
ES (1) ES2689272T3 (es)
MX (1) MX349321B (es)
WO (1) WO2013003895A1 (es)
ZA (1) ZA201400120B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4384852B2 (ja) 2001-01-17 2009-12-16 イントリート ピーティーワイ リミテッド 非機能性ｐ２ｘ７レセプター抗体、癌及びその他の容態の診断及び処置
US8440186B2 (en) 2007-09-14 2013-05-14 Biosceptre International Limited P2X7 epitopes
BRPI0915367B8 (pt) 2008-07-04 2021-05-25 Biosceptre International Ltd peptídeo anti-p2x7
EP3395832B1 (en) 2009-08-20 2021-11-24 Biosceptre (Aust) Pty Ltd Anti p2x7 receptor antibodies and fragments thereof
EP3321285B1 (en) 2009-12-24 2019-04-24 Biosceptre (Aust) Pty Ltd Antibodies to non-functional oligomeric p2x7 receptors
US9562094B2 (en) 2010-09-10 2017-02-07 Biosceptre (Aust) Pty Ltd Companion animal treatments
WO2012090124A2 (en) 2010-12-29 2012-07-05 Ecolab Usa Inc. IN SITU GENERATION OF PEROXYCARBOXYLIC ACIDS AT ALKALINE pH, AND METHODS OF USE THEREOF
WO2012090125A2 (en) 2010-12-29 2012-07-05 Ecolab Usa Inc. Sugar ester peracid on-site generator and formulator
MX349321B (es) 2011-07-01 2017-07-21 Biosceptre (Aust) Pty Ltd Terapia combinada.
US9321664B2 (en) 2011-12-20 2016-04-26 Ecolab Usa Inc. Stable percarboxylic acid compositions and uses thereof
BR122018076176B1 (pt) 2014-12-18 2021-06-01 Ecolab Usa Inc Método para formar ácido peroxifórmico, método para tratar uma superfície, método para tratar um biofilme em uma superfície e método para desinfetar uma superfície da pele
AU2015364492B2 (en) 2014-12-18 2018-08-09 Ecolab Usa Inc. Methods for forming peroxyformic acid and uses thereof
US11040902B2 (en) 2014-12-18 2021-06-22 Ecolab Usa Inc. Use of percarboxylic acids for scale prevention in treatment systems
EP3816294A1 (en) 2015-09-11 2021-05-05 Biosceptre (UK) Limited Chimeric antigen receptors and uses thereof
MX2019004410A (es) 2016-10-21 2019-09-26 Biosceptre Uk Ltd Particulas citotoxicas.
US12058999B2 (en) 2018-08-22 2024-08-13 Ecolab Usa Inc. Hydrogen peroxide and peracid stabilization with molecules based on a pyridine carboxylic acid
MA55805A (fr) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V Inc Métodes de modulation de l'activité immunitaire
WO2021019222A1 (en) * 2019-07-26 2021-02-04 Biosceptre (Uk) Limited P2x7 receptor targeted therapy

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE920765A1 (en) 1991-03-12 1992-09-23 Scripps Research Inst Cell surface receptors homologous to coagulation factors v¹and viii
US5500161A (en) 1993-09-21 1996-03-19 Massachusetts Institute Of Technology And Virus Research Institute Method for making hydrophobic polymeric microparticles
US5985603A (en) 1994-05-27 1999-11-16 Glaxo Group Limited P2x receptor DNA and protein sequence
US5981218A (en) 1995-08-09 1999-11-09 Bristol-Myers Squibb Company Isolated nucleic acid molecules useful as leukemia markers and in breast cancer prognosis and encoded polypeptides
WO1997041222A1 (en) 1996-04-30 1997-11-06 Smithkline Beecham P.L.C. HUMAN P2x4 RECEPTOR SPLICE-VARIANTS
US6303338B1 (en) 1996-08-16 2001-10-16 Human Genome Sciences, Inc. Pancreas-derived plasminogen activator inhibitor
US6306393B1 (en) 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
JP3885177B2 (ja) 1997-03-26 2007-02-21 大塚製薬株式会社 ヒト遺伝子
US6133434A (en) 1997-04-28 2000-10-17 Glaxo Group Limited Purinergic receptor
ES2329851T3 (es) 1998-06-01 2009-12-01 Agensys, Inc. Nuevos antigenos transmembranables expresados en canceres humano y utilizacion de los mismos.
DE19829473C2 (de) 1998-07-01 2000-08-10 Magnus Von Knebel Doeberitz Ch Verfahren zur frühen Diagnose von Carcinomen
EP1157038A4 (en) 1999-02-26 2005-01-19 Smithkline Beecham Corp CLONING OF A P2Y-LIKE 7TM RECEPTOR (AXOR17)
AUPP991199A0 (en) 1999-04-21 1999-05-13 University Of Sydney, The Methods for diagnosing pre-cancerous and cancerous conditions
NL1012452C2 (nl) 1999-06-28 2001-01-02 Univ Delft Tech Werkwijze voor de bereiding van eiwit-agglomeraten, eiwit-agglomeraten, een levensmiddel en een farmaceutisch preparaat die deze bevatten alsmede een inrichting voor het bereiden van eiwit-agglomeraten.
AU1339701A (en) 1999-10-22 2001-05-08 Lifespan Biosciences, Inc. Anti-cancer nucleic acid and protein targets
AUPR201500A0 (en) 2000-12-11 2001-01-11 Biosceptre Pty Ltd Methods for identifying pre-neoplastic and neoplastic states in mammals
JP4384852B2 (ja) 2001-01-17 2009-12-16 イントリート ピーティーワイ リミテッド 非機能性ｐ２ｘ７レセプター抗体、癌及びその他の容態の診断及び処置
JP4467973B2 (ja) * 2001-09-03 2010-05-26 イントリート ピーティーワイ リミテッド 非機能性ｐ２ｘ７リセプターに対応する抗体、癌及びその他の症状の診断及び治療
DK1473367T3 (da) 2003-04-17 2007-10-01 Affectis Pharmaceuticals Ag Midler og fremgangsmåder til diagnosticering og behandling af effektive lidelser
SI2163260T1 (sl) * 2004-01-23 2017-07-31 Msd Italia S.R.L. Nosilci šimpanzjih adenovirusnih cepiv
US7858323B2 (en) 2004-06-09 2010-12-28 The Regents Of The University Of Michigan Phage microarray profiling of the humoral response to disease
GB0419295D0 (en) * 2004-08-31 2004-09-29 Genomica Sau Methods and compositions to prevent neuronal degeneration
US20090215727A1 (en) 2005-05-05 2009-08-27 Medicure International Inc. Inhibition of atp-mediated, p2x7 dependent pathways by pyridoxal-5-phosphate and vitamin b6 related compounds
US7767789B2 (en) 2005-06-02 2010-08-03 University Hopitals of Cleveland Truncated proteins as cancer markers
WO2007027957A2 (en) 2005-08-31 2007-03-08 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in leukemia signaling pathways
WO2008043146A1 (en) 2006-10-10 2008-04-17 Biosceptre International Limited Antibodies against non functional p2x7 receptor
JP2010505426A (ja) 2006-10-10 2010-02-25 バイオスセプター インターナショナル リミテッド 非機能性ｐ２ｘ７受容体に対する抗体を産生するハイブリドーマ
US8440186B2 (en) 2007-09-14 2013-05-14 Biosceptre International Limited P2X7 epitopes
EP2201377B1 (en) 2007-09-14 2012-01-18 Biosceptre International Limited Purinergic (p2x) receptors in extra-cellular body fluid
BRPI0915367B8 (pt) 2008-07-04 2021-05-25 Biosceptre International Ltd peptídeo anti-p2x7
KR20170097234A (ko) * 2008-12-10 2017-08-25 더 헨리 엠. 잭슨 파운데이션 포 더 어드벤스먼트 오브 밀리터리 메디신, 인코포레이티드 유방암 재발 예방용 백신
EP3395832B1 (en) 2009-08-20 2021-11-24 Biosceptre (Aust) Pty Ltd Anti p2x7 receptor antibodies and fragments thereof
EP3321285B1 (en) * 2009-12-24 2019-04-24 Biosceptre (Aust) Pty Ltd Antibodies to non-functional oligomeric p2x7 receptors
WO2011131472A1 (en) 2010-04-22 2011-10-27 Institut Gustave Roussy Compounds and uses thereof to induce an immunogenic cancer cell death in a subject
US9562094B2 (en) 2010-09-10 2017-02-07 Biosceptre (Aust) Pty Ltd Companion animal treatments
MX349321B (es) 2011-07-01 2017-07-21 Biosceptre (Aust) Pty Ltd Terapia combinada.

Also Published As

Publication number Publication date
US9566318B2 (en) 2017-02-14
ZA201400120B (en) 2015-09-30
EP2726095A4 (en) 2015-01-07
CN103702683A (zh) 2014-04-02
US10543262B2 (en) 2020-01-28
CA2840251C (en) 2023-09-12
CA2840251A1 (en) 2013-01-10
ES2689272T3 (es) 2018-11-13
US20190224290A1 (en) 2019-07-25
JP2018087249A (ja) 2018-06-07
CN103702683B (zh) 2017-07-04
WO2013003895A1 (en) 2013-01-10
JP2014520759A (ja) 2014-08-25
US20150004179A1 (en) 2015-01-01
EP2726095A1 (en) 2014-05-07
US20170157229A1 (en) 2017-06-08
EP2726095B1 (en) 2018-06-06
US10245308B2 (en) 2019-04-02
MX2014000199A (es) 2014-06-11
BR112013033974A2 (pt) 2017-02-14
AU2012278921B2 (en) 2016-11-10
JP6490270B2 (ja) 2019-03-27
JP6305920B2 (ja) 2018-04-04
AU2012278921A1 (en) 2014-01-16

Similar Documents

Publication Publication Date Title
MX2014000199A (es) Terapia combinada.
CA145237S (en) Combined cover and saucer
CA139448S (en) Stimulation device
CA143290S (en) Electric fireplace
CA140736S (en) Electric fireplace
CA140737S (en) Electric fireplace
CA145514S (en) Pump
CA147075S (en) Ceiling lamp
CA141065S (en) Dual c clip
TN2014000206A1 (en) Antibody molecules having specificity for human ox40
TN2012000414A1 (en) Forms of rifaximin and uses thereof
CA145612S (en) Patient interface assembly
CA145611S (en) Patient interface assembly
CA143981S (en) Breast pump
CA139066S (en) Stimulation device
CA142744S (en) Epilator
CA145174S (en) Can
CA147873S (en) Teapot
CA143664S (en) Boot
CA141066S (en) Dual c clip
CA145176S (en) Can
CA141191S (en) Packaging
CA141484S (en) Micro audio system
CA143997S (en) Chair
CA146398S (en) Unit for sectional

Legal Events

Date Code Title Description
FG Grant or registration